Security
Mangoceuticals, Inc. Common Stock · MGRX
MGRXNASDAQCommon stockCurrentCIK 1938046Updated Nov 14, 2026
Name history
MANGOCEUTICALS, INC. · through Nov 13, 2026
MGRX price & chart
Loading TradingView…
NASDAQ:MGRX on TradingView ↗In the news
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds ↗
Recent filings
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 3.03, 5.03, 5.07, 9.01
1-A filing
Submission of Matters to a Vote of Security Holders · Shareholder Director Nominations · Other Events
Items 5.07, 5.08, 8.01
PRE 14A filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Show 5 more recent filings
424B5 filing
4 filing
SCHEDULE 13D/A - filed by Cohen Jacob D. regarding MANGOCEUTICALS, INC.
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.01, 3.02, 7.01, 9.01
Termination of a Material Definitive Agreement
Items 1.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 16,531,802Source | 14,792,041Source | 14,172,795Source | 20,842,828Source | 15,237,827Source | 14,449,223Source | 21,753,857Source | 301,447Source | 16,089,573Source | 15,370,511Source | 1,050,793Source | 1,003,287Source |
| Property, Plant and Equipment, NetUSD | 2,049Source | 3,061Source | 1,292Source | 2,304Source | 3,313Source | 1,544Source | 2,556Source | 89,905Source | 1,794Source | 2,806Source | 96,129Source | 117,499Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 15,920,319Source | 14,610,000Source | 13,646,570Source | 20,694,893Source | 14,610,000Source | 13,941,146Source | 21,530,875Source | — | 14,232,484Source | 15,232,617Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 481,281Source | 73,912Source | 228,688Source | 101,019Source | 490,243Source | 174,562Source | 76,496Source | 15,305Source | 1,486,338Source | 58,653Source | 739,006Source | 682,860Source |
| Inventory, NetUSD | — | 13,213Source | — | — | 14,019Source | — | — | 14,452Source | — | — | 18,501Source | — |
| Assets, CurrentUSD | 598,223Source | 104,067Source | 245,687Source | 117,961Source | 517,561Source | 212,472Source | 176,652Source | 89,808Source | 1,547,434Source | 75,595Source | 818,460Source | 694,605Source |
| Operating Lease, Right-of-Use AssetUSD | 11,211Source | 74,913Source | 279,246Source | 27,670Source | 90,011Source | 294,061Source | 43,774Source | 104,792Source | 307,861Source | 59,493Source | 119,262Source | 174,241Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 804,275Source | 1,403,549Source | 1,648,969Source | 1,600,945Source | 1,408,382Source | 974,571Source | 1,503,196Source | 1,259,915Source | 890,568Source | 1,425,463Source | 276,039Source | 389,257Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,389Source | 213Source | 1,803Source | 1,065Source | 2,913Source | 1,698Source | 715Source | 2,362Source | 1,589Source | 325Source | 2,142Source | 1,337Source |
| Additional Paid in CapitalUSD | 53,283,483Source | 31,592,347Source | 57,568,236Source | 50,794,020Source | 30,300,213Source | 57,203,924Source | 45,868,946Source | 12,635,030Source | 55,524,812Source | 35,587,858Source | 12,000,785Source | 2,628,449Source |
| Retained Earnings (Accumulated Deficit)USD | -37,877,913Source | -17,985,966Source | -45,363,283Source | -31,649,804Source | -15,986,733Source | -44,050,630Source | -25,939,986Source | -13,595,754Source | -40,647,480Source | -20,806,595Source | -11,228,173Source | -2,015,756Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,079Source | -1,663Source | -5,198Source | -2,034Source | -1,166Source | -3,193Source | -2,221Source | -70Source | -2,760Source | -9,845Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 15,729,266Source | 13,389,329Source | 12,525,944Source | 19,243,064Source | 13,829,821Source | 13,476,185Source | 20,251,840Source | -958,432Source | 15,200,547Source | 13,946,129Source | 774,754Source | 614,030Source |
| Liabilities and EquityUSD | 16,531,802Source | 14,792,041Source | 14,172,795Source | 20,842,828Source | 15,237,827Source | 14,449,223Source | 21,753,857Source | 301,447Source | 16,089,573Source | 15,370,511Source | 1,050,793Source | 1,003,287Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 804,275Source | 1,391,382Source | 1,398,063Source | 1,600,945Source | 1,378,265Source | 737,606Source | 1,503,196Source | 1,212,202Source | 890,568Source | 1,425,463Source | 211,078Source | 260,577Source |
| Operating Lease, Liability, CurrentUSD | 12,167Source | 69,340Source | 28,301Source | 30,117Source | 67,428Source | 57,058Source | 47,713Source | 65,554Source | 307,823Source | 64,962Source | 63,718Source | 56,725Source |
| Operating Lease, Liability, NoncurrentUSD | — | 12,167Source | 250,906Source | — | 30,117Source | 236,965Source | — | 47,713Source | — | — | 64,961Source | 128,680Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,739Source | -837Source | -2,118Source | -1,181Source | -376Source | -1,533Source | -1,179Source | -36Source | -1,542Source | -1,081Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -7,618,776Source | -1,999,694Source | -1,312,931Source | -5,415,820Source | -3,403,141Source | -4,839,489Source | -20,643,455Source | -8,707,226Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 250Source | — | 9,936Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,090,114Source | 50,979Source | 1,168,280Source | 248,682Source | 624,463Source | 234,088Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | — | 18,501Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,311,343Source | -2,274,781Source | -5,850,255Source | -4,863,776Source | -6,997,375Source | -1,346,518Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 65,000Source | -3,519Source | -43,102Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 3,519Source | 43,102Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 2,285,000Source | 7,270,855Source | 4,128,268Source | 7,057,040Source | 2,049,930Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | 56,146Source | 660,310Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 481,281Source | 73,912Source | 228,688Source | 101,019Source | 174,562Source | 76,496Source | 1,486,338Source | 58,653Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 37,978Source | 50,979Source | — | 248,682Source | 624,463Source | 82,267Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 276,815Source | 276,815Source | 1,122,639Source | 721,533Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 250Source | 250Source | 1,012Source | 9,936Source | 24,889Source | 3,863Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | -18,387Source | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | — | 18,387Source | — | 18,387Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | -125,624Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | -125,625Source | — | — | -19,388Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 311,379Source | 523,855Source | 256,095Source | 1,245,360Source | 1,054,122Source | 1,542,444Source | 3,756,373Source | 3,000,571Source | 3,319,417Source | 1,643,572Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 1,239,942Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 75,850Source | — | — | 21,700Source | — | -13,700Source | 103,513Source | 13,700Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 0Source | 0Source | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,618,218Source | -1,999,233Source | -1,312,653Source | -5,415,818Source | -3,403,150Source | -4,839,391Source | -20,642,994Source | -8,706,145Source | -9,212,417Source | -1,998,055Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -558Source | -461Source | -278Source | -2Source | 9Source | -98Source | -461Source | -1,081Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,912,218Source | -2,293,233Source | -1,606,653Source | -5,709,818Source | -3,697,150Source | -5,133,391Source | -21,818,994Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -75,850Source | -241,620Source | -279,891Source | -147,325Source | -276,815Source | -263,115Source | -2,611,106Source | -735,233Source | 6,473Source | -6,473Source |
| Operating ExpensesUSD | — | — | 7,593,825Source | 1,840,745Source | 1,077,255Source | 5,358,443Source | 3,155,327Source | 4,638,438Source | 18,282,735Source | 8,351,957Source | 9,650,391Source | 1,996,432Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 655,000Source | 4,625,355Source | 1,328,268Source | 6,200,000Source | 2,000,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 84,246Source | 133,368Source | 68,757Source | 168,109Source | 67,864Source | 109,306Source | 456,021Source | 615,873Source | 731,493Source | 8,939Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -7,542,926Source | -1,758,074Source | -1,033,040Source | -5,268,495Source | -3,126,326Source | -4,576,374Source | -18,032,349Source | -7,971,993Source | -9,218,890Source | -1,991,582Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -7,618,776Source | -1,999,694Source | -1,312,931Source | -5,415,820Source | -3,403,141Source | -4,839,489Source | -20,643,455Source | -8,707,226Source | -9,212,417Source | -1,998,055Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -558Source | -461Source | -278Source | -2Source | 9Source | -98Source | -461Source | -1,081Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,618,218Source | -1,999,233Source | -1,312,653Source | -5,415,818Source | -3,403,150Source | -4,839,391Source | -20,642,994Source | -8,706,145Source | -9,212,417Source | -1,998,055Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.69Source | -1.14Source | -0.09Source | -0.57Source | -0.22Source | -1.12Source | -2.17Source | -4.84Source | -0.57Source | -0.19Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.69Source | -1.14Source | -0.09Source | -0.57Source | -0.22Source | -1.12Source | -2.17Source | -4.84Source | -0.57Source | -0.19Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 11,524,275Source | 2,013,848Source | 17,119,619Source | 9,983,376Source | 16,481,607Source | 4,593,062Source | 10,071,609Source | 1,978,966Source | 16,113,029Source | 10,798,083Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 11,524,275Source | 2,013,848Source | 17,119,619Source | 9,983,376Source | 16,481,607Source | 4,593,062Source | 10,071,609Source | 1,978,966Source | 16,113,029Source | 10,798,083Source |
| Interest Expense (non-operating)USD | — | — | 75,850Source | — | — | 21,700Source | — | -13,700Source | 103,513Source | 13,700Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 276,815Source | 276,815Source | 1,122,639Source | 721,533Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | -125,624Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 311,379Source | 523,855Source | 256,095Source | 1,245,360Source | 1,054,122Source | 1,542,444Source | 3,756,373Source | 3,000,571Source | 3,319,417Source | 1,643,572Source |
| Gross ProfitUSD | — | — | 50,899Source | 82,671Source | 44,215Source | 89,948Source | 29,001Source | 62,064Source | 250,386Source | 379,964Source | 431,501Source | 4,850Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 6,473Source |
| Labor and Related ExpenseUSD | — | — | 542,420Source | 242,941Source | 427,298Source | 628,343Source | 346,860Source | 349,783Source | 1,348,051Source | 1,063,781Source | 977,890Source | — |
| Marketing and Advertising ExpenseUSD | — | — | 104,914Source | 251,330Source | 301,445Source | 258,295Source | 94,073Source | 281,732Source | 822,860Source | 1,478,663Source | 2,097,505Source | 352,860Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,912,218Source | -2,293,233Source | -1,606,653Source | -5,709,818Source | -3,697,150Source | -5,133,391Source | -21,818,994Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -75,850Source | -241,620Source | -279,891Source | -147,325Source | -276,815Source | -263,115Source | -2,611,106Source | -735,233Source | 6,473Source | -6,473Source |
| Operating ExpensesUSD | — | — | 7,593,825Source | 1,840,745Source | 1,077,255Source | 5,358,443Source | 3,155,327Source | 4,638,438Source | 18,282,735Source | 8,351,957Source | 9,650,391Source | 1,996,432Source |
Offerings
Registration 333-292711
Filing attachments
ex4-1.htm · 1-A · 2026-11-12
Exhibit 4.1 SUBSCRIPTION AGREEMENT MANGOCEUTICALS, INC. A TEXAS CORPORATION This is a Subscription for 8% Series D Convertible Cumulative Preferred Stock (also referred to herein as the “Series D Preferred Stock” or the “Shares”) of Mangoceuticals, Inc. (the “Company”) THIS SUBSCRIPTION AGREEMENT (this “Agreement” or this “Subscription”) is made and entered into as of the date of the Subscriber’s electronic signature below, by and between the undersigned (the “Subscriber,” “Investor,” o…
Read attachment ↗ex4-1.htm · 8-K · 2026-10-09
Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT MANGOCEUTICALS, INC. Warrant Issue Shares: 657,000 Date: October 9, 2026 THIS COMMON STOCK PURCHASE WARRANT (this “ Warrant ”) certifies that, for value received, GHS Investments or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (the “ Initial Exercise Date ”) and on or prior to 5:00 p.m. …
Read attachment ↗ex99-1.htm · 8-K · 2026-10-09
Exhibit 99.1 Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX / October 9, 2026 / Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and Peac…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-01
Exhibit 99.1 Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock DALLAS, TEXAS, October 1, 2026 (GLOBE NEWSWIRE) - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling health and we…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination Dallas, Texas - August 4, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in …
Read attachment ↗ex99-1.htm · 425 · 2026-07-30
Exhibit 99.1 Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology Business Combination Agreement to Bring Nuclea’s Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS - July 30, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that it has entered into a definitive business combination agreement …
Read attachment ↗